Vaccinating the world against the coronavirus is a lucrative business, and the shifting winds of the pandemic have big implications for the competitive landscape of vaccine makers. The principal reason why the vaccine landscape is changing is that some of the products on the market seem to be more effective against the delta variant than others. The two-dose jabs made by Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) remain the gold standard for generating durable immunity against the coronavirus.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting